Warfarin Glycosylation Invokes a Switch from Anticoagulant to Anticancer Activity

Abstract

Changing lanes! Glycosylation of the classical pharmacophore warfarin fundamentally alters the drug's mechanism-of-action, leading to a dramatic reduction in anticoagulant function and a concomitant marked increase in anticancer cytotoxicity. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.